Form 8-K - Current report:
SEC Accession No. 0001628280-24-003865
Filing Date
2024-02-08
Accepted
2024-02-08 16:07:18
Documents
18
Period of Report
2024-02-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jan-20240208.htm   iXBRL 8-K 32104
2 EX-10.101 ex10101_icgjanonefourthame.htm EX-10.101 86073
3 EX-10.102 ex10102_livejanonefirstame.htm EX-10.102 78933
4 EX-10.103 ex10103_janonepromissoryno.htm EX-10.103 95534
5 EX-10.104 ex10104_janonepromissoryno.htm EX-10.104 94937
  Complete submission text file 0001628280-24-003865.txt   593284

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jan-20240208.xsd EX-101.SCH 1929
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jan-20240208_lab.xml EX-101.LAB 25156
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jan-20240208_pre.xml EX-101.PRE 13069
19 EXTRACTED XBRL INSTANCE DOCUMENT jan-20240208_htm.xml XML 2812
Mailing Address 325 E. WARM SPRINGS ROAD SUITE 102 LAS VEGAS NV 89119
Business Address 325 E. WARM SPRINGS ROAD SUITE 102 LAS VEGAS NV 89119 702-997-5968
JanOne Inc. (Filer) CIK: 0000862861 (see all company filings)

EIN.: 411454591 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19621 | Film No.: 24609041
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)